GHRS
OtherGH Research PLC
$22.44+1.16 (+5.45%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving GHRS Today?
No stock-specific AI insight has been generated for GHRS yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume375K
Avg Volume (10D)—
Shares Outstanding68.6M
GHRS News
20 articles- GH Research Announces Pricing of $117.5 Million Underwritten OfferingYahoo Finance·Apr 29, 2026
- FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit.Yahoo Finance·Apr 24, 2026
- FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers GainYahoo Finance·Apr 24, 2026
- ‘Can I have some, please?’: Trump jokes as he signs psychedelics order after Joe Rogan push. These stocks soarYahoo Finance·Apr 22, 2026
- How Trump Sent Psychedelics-Tied Compass Pathways And Others FlyingYahoo Finance·Apr 20, 2026
- Sector Update: Health Care Stocks Fall Late AfternoonYahoo Finance·Apr 20, 2026
- Market Feels Weak, But Stocks Tell StoriesYahoo Finance·Apr 20, 2026
- GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental IllnessYahoo Finance·Apr 20, 2026
- Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental IllnessYahoo Finance·Apr 20, 2026
- Psychedelic stocks soar after Trump signs executive order to fast-track treatmentsYahoo Finance·Apr 20, 2026
- Trump Trade: President to sign order on psychedelic used for PTSDYahoo Finance·Apr 17, 2026
- Here's Why We're Not At All Concerned With GH Research's (NASDAQ:GHRS) Cash Burn SituationYahoo Finance·Apr 4, 2026
- Will Psychedelic Stocks Have A Trippy Ride Under RFK Jr.?Yahoo Finance·Apr 2, 2026
- GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRDYahoo Finance·Mar 25, 2026
- What Does GH Research PLC (GHRS)’s Clinical Progress Updates Say?Yahoo Finance·Mar 25, 2026
- Weekly Roundup on the Cannabis Sector & Psychedelic SectorYahoo Finance·Mar 8, 2026
- Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study resultsYahoo Finance·Mar 6, 2026
- GH Research Reports Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 5, 2026
- RBC Capital Cite GH Research PLC’s (GHRS) Long-Term Sales Potential Following Psychedelics SymposiumYahoo Finance·Feb 19, 2026
- Psychedelics stocks rise as Compass’ psilocybin drug heads to FDABiopharmadive·Feb 18, 2026
All 20 articles loaded
Price Data
Open$21.67
Previous Close$21.28
Day High$21.94
Day Low$21.00
52 Week High—
52 Week Low—
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume375K
Avg Volume (10D)—
Shares Outstanding68.6M
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SIC—
CIK—
Composite FIGI—
Share Class FIGI—